Nature Biotechnology. 1 October 2018: Sarwish Rafiq, Oladapo O Yeku, Hollie J Jackson, Terence J Purdon, Dayenne G van Leeuwen, Dylan J Drakes, Mei Song, Matthew M Miele, Zhuoning Li, Pei Wang, Su Yan, Jingyi Xiang, Xiaojing Ma, Venkatraman E Seshan, Ronald C Hendrickson, Cheng Liu & Renier J Brentjens
Molecular Therapy. 06 June 2018: Eric L. Smith, Mette Staehr, Reed Masakayan, Ishan J. Tatake, Terence J. Purdon, Xiuyan Wang, Pei Wang, Hong Liu, Yiyang Xu, Sarah C. Garrett-Thomson, Steven C. Almo, Isabelle Riviere, Cheng Liu, and Renier J. Brentjens
JCI Insight. 22 February 2018: Mahiuddin Ahmed, Andres Lopez-Albaitero, Dmitry Pankov, Brian H. Santich, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang, Aisha N. Hasan, Annamalai Selvakumar, Richard J. O’Reilly, Cheng Liu, and Nai-Kong V. Cheung
Pharmacogenomics. 23 January 2017: Yining Sun, Lingfei Mo, Xiuyuan Feng, Dongmei Yang, Taochao Tan, Lingxia Zeng, Lingyun Hui, Yawen Wang, Cheng Liu & Lan He
Phage Display. 8 November 2017: Zhihao Wu, Brian H. Santich, Hong Liu, Cheng Liu & Nai-Kong V. Cheung
Leukemia. 12 July 2017: M D Mathias, J T Sockolosky, A Y Chang, K S Tan, C Liu, K C Garcia & D A Scheinberg
Leukemia. 7 December 2016: S Rafiq, T J Purdon, A F Daniyan, M Koneru, T Dao, C Liu, D A Scheinberg & R J Brentjens
The Journal of Clinical Investigation. 19 June 2017: Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa D. Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Cheng Liu, and David A. Scheinberg
Clinical Cancer Research. 15 January 2017: Hong Liu, Yiyang Xu, Jingyi Xiang, Li Long, Shon Green, Zhiyuan Yang, Bryan Zimdahl, Jingwei Lu, Neal Cheng, Lucas H Horan, Bin Liu, Sun Yan, Pei Wang, Juan Diaz, Lu Jin,Yoko Nakano, Javier F Morales, Pengbo Zhang, Lian-xing Liu, Binnaz K Staley, Saul J Priceman, Christine E. Brown, Stephen J. Forman, Vivien W Chan & Cheng Liu
Oncoimmunology. 3 August 2016: Leonid Dubrovsky, Elliott Joseph Brea, Dmitry Pankov, Emily Casey, Tao Dao, Cheng Liu, and David A. Scheinberg
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.